# Biomarkers

## Part 1: Technologies & Applications

**By**

**Prof. K.K. Jain**
**MD, FRACS, FFPM**
**Jain PharmaBiotech**
**Basel, Switzerland**

## September 2017

**A Jain PharmaBiotech Report**

# AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 470 publications include 28 books (5 as editor+ 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. The following Jain PharmaBiotech reports are relevant to biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Handbook of Neuroprotection" (Springer 2011), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited "Applied Neurogenomics" (Springer 2015).

.

**September 2017**
**Copyright © 2017 by**

**Jain PharmaBiotech**
**Bläsiring 7**
**CH-4057 Basel**
**Switzerland**

**Tel & Fax: +4161-6924461**
**Email: info@pharmabiotech.ch**
**Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS


**0. Executive Summary ..... 28**

**1. Introduction ..... 30**
**Definitions ..... 30**
**Historical aspects of biomarkers ..... 30**
**Classification of biomarkers ..... 31**
Biomarker as a response to therapeutic intervention ..... 32
Pharmacokinetic/pharmacodynamics biomarkers ..... 32
Predictive biomarkers ..... 32
Valid biomarkers ..... 33
**Types of biomarkers ..... 34**
Genes as biomarkers ..... 34
*Silent gene mutations ..... 34*
Epigenetic biomarkers ..... 34
Proteins as biomarkers ..... 35
*Proteomics ..... 35*
DNA biomarkers ..... 36
Mitochondrial DNA ..... 36
*Mitochondrial mutations ..... 36*
RNA biomarkers ..... 36
*Transcriptomics ..... 37*
*MicroRNAs ..... 38*
Metabolomics ..... 38
Glycomics ..... 38
Single nucleotide polymorphisms ..... 39
*Haplotyping ..... 39*
Cell biomarkers of disease ..... 40
Stem cell biomarkers ..... 40
*Association of stem cell biomarkers with disease ..... 40*
*Cancer stem cell biomarkers ..... 41*
*Endoglin as a functional biomarker of stem cells ..... 41*
*p75NTR as a biomarker to isolate adipose tissue-derived stem cells ..... 41*
*Protein expression profile as biomarker of stem cells ..... 41*
*STEMPRO® EZChek™ for analysis of biomarkers of hESCs ..... 42*
*SSEA-4 as biomarker of MSCs ..... 42*
Gaseous mediators as biomarkers of disease ..... 42
Autoantibodies as biomarkers of autoimmune diseases ..... 42
Comparison of various types of biomarkers ..... 43
**Biomarkers and systems biology ..... 43**
Systems biology approach to biomarker identification ..... 45
**Relation of biomarkers to other technologies and healthcare ..... 45**
Biomarkers and translational medicine ..... 46
Role of biomarkers in monitoring of diseases ..... 47
Limitations of use of biomarkers in healthcare ..... 47

**2. Technologies for Discovery of Biomarkers ..... 48**
**Introduction ..... 48**
The ideal biomarker ..... 48
**Genomic technologies ..... 48**
Gene expression ..... 48
*Whole genome expression array ..... 49*
*Gene expression profiling on whole blood samples ..... 50*
*Profiling gene expression patterns of white blood cells ..... 50*
Tissue microarrays for study of biomarkers ..... 50
**Technologies for detection of miRNAs as biomarkers ..... 51**
Microarrays for analysis of miRNA gene expression ..... 51
*Microarrays vs quantitative PCR for measuring miRNAs ..... 52*
Point-of-care detection of circulating miRNAs as biomarkers ..... 52
**Epigenomic technologies ..... 52**
Discovery of methylation biomarkers ..... 53
**Proteomic technologies ..... 54**
2D GE ..... 55
ProteoCarta® integrated proteomics discovery platform ..... 55
Isotope-coded affinity tags ..... 56
Liquid chromatography-MS/MS ..... 56
Lucid Proteomics System ..... 57
Magnetics beads for protein biomarker discovery ..... 57
MASStermind™ ..... 57

Combined analysis of protein and nucleic-acid biomarkers ..... 58
Mass spectrometry ..... 58
*2D PAGE and mass spectrometry ..... 59*
*Imaging mass spectrometry ..... 59*
*MALDI mass spectrometry for biomarker discovery ..... 60*
*Quantitative tandem MS ..... 60*
*Single-molecule mass spectrometry using a nanopore ..... 61*
*Requirements for MS-based proteomic biomarker development ..... 61*
Nucleic Acid Programmable Protein Array ..... 61
Protein tomography ..... 62
Protein biochips/microarrays and biomarkers ..... 62
*Antibody array/affinity proteomics-based biomarker discovery ..... 62*
*Detection of biomarkers using peptide array technology ..... 64*
*ProtoArray® ..... 64*
*Protein nanobiochip ..... 64*
Gene expression microarray data as a source of protein biomarkers ..... 65
Quantification of protein biomarkers ..... 65
*Multiple reaction monitoring assays ..... 65*
*Real-time PCR for quantification of protein biomarkers ..... 66*
*CyTOF for quantification of biomarkers ..... 66*
Search for biomarkers in body fluids ..... 67
Challenges and strategies for discovey of protein biomarkers in plasma ..... 67
*Technologies for removal of highly abundant proteins in blood ..... 67*
*3D structure of CD38 as a biomarker ..... 68*
*BD™ Free Flow Electrophoresis System ..... 68*
*Isotope tags for relative and absolute quantification ..... 69*
*Plasma protein microparticles as biomarkers ..... 69*
*Proteome partitioning ..... 70*
*Stable isotope tagging methods ..... 70*
*Technology to measure both the identity and size of the biomarker ..... 71*
*Selected reaction monitoring MS ..... 71*
*Targeted MS for verification of biomarkers ..... 71*
Biomarkers in the urinary proteome ..... 72
Peptides as biomarkers of disease ..... 73
*Analysis of peptides in bodily fluids ..... 73*
*Antibody biomarker discovery via evolution of peptides ..... 74*
*Serum peptidome patterns ..... 74*
*SISCAPA method for quantitating proteins and peptides in plasma ..... 75*
Comparison of proteomic profiling technologies for discovery of biomarkers ..... 75
Verification for interlaboratory reproducibility of protein biomarkers ..... 75
Significance of similar protein biomarkers in different tissues ..... 76
**Glycomic technologies ..... 77**
Cellular glycomics for discovery of cellular biomarkers ..... 77
**Metabolomic technologies ..... 77**
Genome-wide association studies for identification of metabolic biomarkers ..... 78
*Genetic influences on human blood metabolites ..... 78*
Lipid profiling ..... 79
Mass spectrometry for discovery of metabolic biomarkers in plasma ..... 79
Role of metabolomics in biomarker identification and pattern recognition ..... 80
Urinary profiling by capillary electrophoresis ..... 80
Validation of biomarkers in large-scale human metabolomics studies ..... 80
**Lipidomics ..... 80**
**Disease biomarkers in breath ..... 81**
Portable breath test for volatile organic compounds ..... 81
Detection of breath biomarkers by sensation technology ..... 82
Detection of breath biomarkers by nanosensors ..... 82
Detection of breath biomarkers optical frequency comb spectroscopy ..... 82
*Detection of breath biomarkers by infrared absorption spectroscopy ..... 83*
Detection of biomarkers by electronic nose ..... 83
**Fluorescent indicators for biomarkers ..... 83**
**Molecular imaging technologies ..... 84**
Computer tomography ..... 84
Magnetic resonance imaging ..... 84
Positron emission tomography ..... 85
Advantages of imaging biomarkers ..... 85
Monitoring in vivo gene expression by molecular imaging ..... 85
Molecular imaging in vivo as a biomarker ..... 86
Challenges and future of molecular imaging ..... 87
*Basic research in molecular imaging ..... 87*
*Imaging intracellular NADH as a biomarker of disease ..... 87*
*Devices for molecular imaging ..... 87*

*Imaging biomarkers in clinical trials* ..... *87*
*Molecular imaging in clinical practice* ..... *88*
**Nuclear magnetic resonance** ..... **88**
Chemical derivatization to enhance biomarker detection by NMR ..... 88
Fluxomics by using NMR ..... 89
**Nanobiotechnology** ..... **89**
Dip Pen Nanolithography ..... 89
Nanomaterials for biolabeling ..... 90
*Quantum dot molecular labels* ..... *91*
*Bioconjugated QDs for multiplexed profiling of biomarkers* ..... *91*
*Magnetic nanotags for multipley detection of biomarkers* ..... *91*
Nanoparticles for molecular imaging ..... 92
Nanoparticles for discovering biomarkers ..... 92
Nanoproteomics and biomarkers ..... 93
*High-field asymmetric waveform ion mobility mass spectrometry* ..... *93*
Nanosensors for measuring biomarkers in blood ..... 93
Nanobiochip sensor technique for analysis of oral cancer biomarkers ..... 93
Future prospects of application of nanobiotechnology for biomarkers ..... 94
**Bioinformatics** ..... **94**
Biomarker Workflow Guide ..... 94
Analysis of microarray data for selecting useful biomarkers ..... 95
Role of bioinformatics in discovery of protein biomarkers ..... 95
Role of bioinformatics in detection of cancer biomarkers ..... 96
Biomarker databases ..... 96
Gene networks as biomarkers ..... 97
Role of bioinformatics in integrating various data and biomarker discovery ..... 97
**Evaluation of biomarker studies** ..... **97**

**3. Biomarkers and Molecular Diagnostics ..... 100**
**Introduction** ..... **100**
**Molecular diagnostic technologies** ..... **100**
Polymerase chain reaction ..... 100
*Amplification* ..... *100*
*Target selection* ..... *101*
*Detection of amplified DNA* ..... *101*
*Limitations of PCR* ..... *101*
Real-time PCR systems ..... 102
*Limitations of real-time PCR* ..... *102*
*Future applications of real-time qPCR* ..... *103*
*Real-time qPCR for quantification of circulating mtDNA* ..... *103*
Combined PCR-ELISA ..... 103
Non-PCR methods ..... 104
*Linked Linear Amplification* ..... *104*
Transcription mediated amplification ..... 104
Rapid analysis of gene expression ..... 104
WAVE nucleic acid fragment analysis system ..... 105
DNA probes with conjugated minor groove binder ..... 105
Rolling circle amplification technology ..... 106
*Gene-based diagnostics through RCAT* ..... *106*
*RCAT-immunodiagnostics* ..... *107*
*RCAT-biochips* ..... *107*
*RCAT-pharmacogenomics* ..... *107*
Circle-to-circle amplification ..... 107
Biochips and microarrays ..... 108
*Applications of biochips/microarrays* ..... *108*
*Role of biochip/microarrays in discovery of biomarkers* ..... *109*
**Biomarkers and high throughput molecular screening** ..... **109**
**Detection and expression profiling of miRNA** ..... **110**
Real-time PCR for expression profiling of miRNAs ..... 110
Use of LNA to explore miRNA ..... 110
Microarrays for analysis of miRNA gene expression ..... 110

**4. Biomarkers for Drug Discovery & Development ..... 112**
**Introduction** ..... **112**
**Biomarker technologies for drug discovery** ..... **112**
Proteomics-based biomarkers for drug discovery ..... 112
Chemoproteomics ..... 113
*Activity-based chemical proteomics* ..... *113*
Transcriptomics for drug discovery ..... 113
Metabolomics for drug discovery ..... 114
**Biomarkers and drug safety** ..... **114**

Biomarkers of adverse drug reactions ..... 114
Applications of biomarkers in drug safety studies ..... 115
Genomic technologies for toxicology biomarkers ..... 115
Proteomic technologies for toxicology biomarkers ..... 116
Metabonomic technologies for toxicology biomarkers ..... 116
Integration of genomic and metabonomic data to develop toxicity biomarkers ..... 116
Toxicology studies based on biomarkers ..... 117
*Biomarkers of hepatotoxicity ..... 118*
*Biomarkers of nephrotoxicity ..... 119*
*Cardiotoxicity ..... 120*
*Neurotoxicity ..... 121*
**Applications of biomarkers for drug development ..... 121**
Application of metabonomics/metabolomics for drug development ..... 122
Role of pharmacokinetic/pharmacodynamic biomarkers in drug development ..... 123
Molecular imaging as a biomarker in drug development ..... 124
*Molecular imaging in preclinical studies ..... 124*
*Molecular imaging in clinical trials ..... 125*
*Prospects of molecular imaging in drug discovery and development ..... 125*
Biomarkers in clinical trials ..... 126
*NIH recommendations on the use of biomarkers in clinical trials ..... 126*
*Advantages of biomarkers for drug development ..... 127*
*Limitations and problems with use of biomarkers in clinical trials ..... 128*
Application of biomarkers by the pharmaceutical companies ..... 128
Role of biomarkers in vaccine development ..... 130
Role of biomarkers in relation to stage of drug discovery and development ..... 130
Role of biomarkers for drug development in cardiovascular disorders ..... 130
Role of biomarkers for drug development in neurological disorders ..... 131
Significance of biomarkers in drug development ..... 131
Pharmacogenomic biomarker information in drug labels ..... 132
**Organizations & resources for biomarker-based drug development ..... 132**
Biomarker Alliance ..... 132
Biomarkers Consortium ..... 133
Molecular Libraries and Imaging Roadmap of NIH ..... 134
Rare Diseases Clinical Research Consortia ..... 134
**Future of biomarker-based drug development ..... 134**

**5. Role of Biomarkers in Healthcare ..... 136**
**Introduction ..... 136**
**Biomarkers of inflammation ..... 137**
ESR and CRP as biomarkers of inflammation ..... 137
Metabolic biomarkers of inflammation ..... 138
YKL-40 as a biomarker inflammation and predictor of mortality ..... 138
**Biomarkers of allergic disorders ..... 138**
**Biomarkers of oxidative stress ..... 139**
1,4-dihydroxynonane-mercapturic acid ..... 139
Oxidized phospholipids ..... 139
Oxidative DNA damage ..... 140
Proteins as biomarkers of oxidative stress in diseases ..... 140
Testing for oxidative stress ..... 140
**Biomarkers of hypoxia ..... 141**
Pathophysiology of hypoxia ..... 141
Hypoxia inducible factor as biomarker of hypoxia and response to oxygenation ..... 141
Identification of hypoxia biomarkers from exhaled breath ..... 141
Metabolic biomarkers of hypoxia ..... 142
**Biomarkers of liver disease ..... 142**
Breath biomarkers of liver disease ..... 142
Biomarkers of liver injury ..... 142
Fibrosis and cirrhosis of liver ..... 143
FibroMax ..... 143
Hepatic encephalopathy ..... 143
miRNA biomarkers of liver disease ..... 144
Viral hepatitis B and C ..... 144
*Biomarkers of hepatitis C ..... 144*
*Biomarkers of hepatitis B ..... 145*
**Biomarkers of pancreatitis ..... 145**
**Biomarkers of renal disease ..... 146**
Biomarkers of lupus nephritis ..... 146
Biomarkers of diabetic nephropathy ..... 147
Cystatin C as biomarker of glomerular filtration rate (GFR) ..... 147
Estimated GFR and albuminuria as biomarkers of chronic kidney disease ..... 147
Proteomic biomarkers of acute kidney injury ..... 148

Symmetric dimethylarginine as biomarker of chronic kidney disease in dogs ..... 148
Troponin-T as a biomarker for predicting end-stage renal disease ..... 148
**Biomarkers in pediatrics ..... 148**
Pediatric critical care ..... 148
Biomarkers of acute kidney injury in children ..... 149
**Biomarkers of miscellaneous disorders ..... 149**
Biomarkers of carbon monoxide poisoning ..... 149
Biomarkers of Castleman disease ..... 149
Biomarkers of erectile dysfunction ..... 150
Biomarkers of fever ..... 150
Biomarkers of heat stroke ..... 151
Biomarkers of hyponatremia ..... 151
Biomarkers of inflammatory bowel disease ..... 151
Biomarkers of radiation injury ..... 152
Biomarkers for prediction of all-cause mortality ..... 153
Biomarkers common to multiple diseases ..... 153
Nasal nitric oxide as a biomarker of response to rhinosinusitis therapy ..... 154
**Biomarkers of gene-environmental interactions in human disease ..... 154**
**Application of biomarkers in animal health ..... 155**

**6. Biomarkers in Metabolic Disorders ..... 158**
Biomarkers of acute intermittent porphyria ..... 158
Liver X receptors ..... 158
Biomarkers of diabetes mellitus ..... 158
*β-cell function as biomarker of diabetes ..... 160*
*Biomarkers of hyperglycemia ..... 160*
*Biomarkers of diabetes-associated oxidative stress ..... 160*
*Biomarkers of inflammation associated with diabetes ..... 160*
*Biomarkers of renal complications in diabetes mellitus type 2 ..... 161*
*Biomarkers of diabesity ..... 161*
*Biomarkers of prediabetes ..... 161*
*Biomarkers of insulin resistance ..... 161*
*Glycosylated hemoglobin in diabetes mellitus ..... 162*
*Glycated albumin as a biomarker of diabetes mellitus ..... 162*
*Low C-peptide as a biomarker of complications of diabetes type 1 ..... 162*
*Personalized management of diabetes mellitus based on biomarkers ..... 163*
Biomarkers of metabolic syndrome ..... 163
*Adiponectin ..... 163*
*Cystatin C ..... 164*
*Human plasma lipidome ..... 164*
*Neurotensin as biomarker of obesity ..... 165*

**7. Biomarkers in Immune Disorders ..... 168**
**Introduction ..... 168**
**Biomarkers relevant to organ transplantation ..... 168**
Biomarkers of graft versus host disease ..... 168
Biomarkers of renal allograft failure ..... 169
Biomarkers of renal transplant tolerance ..... 170
Biomarkers of lung transplant rejection ..... 171
Biomarkers of GVHD following transplantation of hematopoietic cells ..... 171
Plasma biomarkers of response to therapy of GVHD ..... 171
**Systemic lupus erythematosus ..... 172**
Adiponectin as biomarker of SLE ..... 172
Current management and need for biomarkers of SLE ..... 172
Role of collaborative efforts and databases of SLE biomarkers ..... 173
C4d-bearing reticulocytes ..... 173
CB-CAPS ..... 173
Epigenetic biomarkers of SLE ..... 173
Genetic loci of SLE ..... 174
HMGB1 ..... 174
**Biomarkers of systemic sclerosis ..... 174**

**8. Biomarkers of Musculoskeletal Disorders ..... 176**
**Introduction ..... 176**
**Muscle disorders ..... 176**
Biomarkers of muscle fatigue during exercise ..... 176
Biomarkers of mitochondrial content in skeletal muscle ..... 176
Idiopathic inflammatory myopathies ..... 177
**Rheumatoid arthritis ..... 177**
Assays for biomarkers of RA ..... 178
Biomarkers for personalizing therapy of rheumatoid arthritis ..... 178

Circulating cytokines in RA ..... 179
Epigenetic biomarkers of rheumatoid arthritis ..... 179
miRNA biomarkers in RA ..... 179
Serum CRP in RA ..... 180
**Biomarkers of spondylarthritis ..... 180**
Biomarkers of axial spondyloarthritis ..... 181
Biomarkers of psoriatic arthritis ..... 181
**Osteoarthritis ..... 181**
Molecular pathophysiology of OA ..... 182
Biomarkers of osteoarthritis ..... 182
Assays for biomarkers of OA ..... 183
Biomarkers of OA ..... 183
Concluding remarks and future prospects of biomarkers of OA ..... 184
**Biomarkers of osteoporosis ..... 184**
Assays for detection of biomarkers of osteoporosis ..... 184
Bone imaging with quantitative CT and MRI ..... 185
Circulating miRNAs as biomarkers of osteoporosis ..... 185
Dual x-ray absorptiometry ..... 186
Utility of biomarkers of osteoporosis ..... 186
**Biomarkers of osteonecrosis ..... 186**
Osteonecrosis in Gaucher's disease ..... 186

**9. Biomarkers of Infectious Diseases ..... 188**
**Introduction ..... 188**
**Technologies for discovery of biomarkers of infection ..... 188**
Chemokines as biomarkers of infection ..... 188
Endotoxin as biomarker of infection ..... 188
Proteomics for discovering biomarkers of infections ..... 188
Soluble urokinase plasminogen activator receptor ..... 189
**Sepsis ..... 189**
Biomarkers of sepsis ..... 190
*Circulating CPS-1 as biomarkers of organ damage in sepsis ..... 191*
*CoQ10 level reduction in septic shock ..... 191*
*Multibiomarker-based outcome risk stratification of septic shock ..... 192*
*Nitric oxide as a biomarker of sepsis ..... 192*
*SuPAR as a biomarker of sepsis ..... 192*
Systemic inflammatory response syndrome ..... 193
**Tuberculosis ..... 193**
Conventional diagnosis of tuberculosis ..... 194
Molecular diagnostics for tuberculosis ..... 194
Biomarkers for tuberculosis ..... 194
Biomarkers of pulmonary tuberculosis in the breath ..... 195
**Biomarkers of viral infections ..... 195**
Viral hepatitis ..... 195
Biomarkers of SARS ..... 197
Biomarkers of HIV ..... 198
**Biomarkers in parasitic infections ..... 199**
Role of biomarkers in malaria ..... 199
Identification of biomarkers in Schistosomiasis infections ..... 199
**Diagnostic & therapeutic applications of biomarkers of infections ..... 200**
Biomarkers to discriminate bacterial from nonbacterial respiratory infections ..... 200
Procalcitonin as a guide to antibiotic therapy in infections ..... 200

**10. Biomarkers of Genetic Disorders ..... 202**
**Introduction ..... 202**
**Biomarkers of Down's syndrome ..... 202**
**Biomarkers of muscular dystrophy ..... 202**
**Biomarkers of phenylketonuria ..... 203**
**Genetic biomarkers of psoriasis ..... 203**
**Biomarkers of lysosomal storage disorders ..... 204**
Biomarkers of Niemann-Pick disease ..... 204
*Bile acids as biomarkers for the early diagnosis of NPD ..... 204*
*Cholesterol oxidation products as biomarkers of NPD ..... 204*
Biomarkers of mucopolysaccharidoses ..... 205
*Proteomic technologies for biomarkers of MPS ..... 205*
*Glycan-based biomarkers for MPS ..... 206*
*Biomarkers of LSD ..... 206*
*Prenatal diagnosis of LSD ..... 206*
Biomarkers of Fabry's disease ..... 207

**11. Biomarkers of Aging ..... 208**

**Introduction** ..... **208**
**Biomarkers of biological age** ..... **209**
**Gene variants as determinants of biological age** ..... **210**
Gene expression profiles for calculating transcriptomic age ..... 210
**Biomarkers of healthy aging** ..... **210**
**Biomarkers of longevity** ..... **211**
Healthy aging index ..... 211
Effect of calorie restriction on biomarkers of longevity ..... 211
**Biomarkers as predictors of mortality with aging** ..... **211**
Genetic biomarkers of aging ..... 212
Genetic signatures of longevity ..... 212
**Low serum thyroid hormone level as biomarker of longevity** ..... **212**
**Metabolomic biomarkers of aging** ..... **213**
**Mitochondrial mutations as biomarkers of aging** ..... **213**
**Protein biomarkers of aging** ..... **213**
Carbamylated proteins as biomarkers of aging ..... 213
Proteomic biomarkers of muscle aging ..... 214
Role of humanin in age-related diseases ..... 214
**Role of bioinformatics in search for biomarkers of aging** ..... **214**
**Aging biomarkers in a genetically homogeneous population** ..... **215**
**Telomere attrition as aging biomarker** ..... **215**

**12. Nutritional Biomarkers ..... 216**
**Introduction** ..... **216**
**Biomarkers of Nutrition for Development project** ..... **216**
**Biomarkers in nutritional epidemiology** ..... **216**
**Biomarkers of nutritional status** ..... **217**
Ferritin as biomarker of nutritional status ..... 217
Folate biomarkers related to nutritional health status ..... 218
Iodine as biomarker of nutritional status ..... 218
Zinc as a biomarker of nutritional status ..... 219
**Biomarkers of branched chain amino acid status** ..... **219**
**Biomarkers of caloric restriction** ..... **219**
**Biomarkers of malnutrition** ..... **219**
Maternal nutrition during early pregnancy causes epigenetic changes ..... 220
**Proteomic biomarkers and nutrition** ..... **220**
**Vitamin deficiency as biomarker of disease** ..... **220**
Vitamin A biomarkers ..... 220
Vitamin B12 deficiency ..... 221
Vitamin D deficiency as a biomarker of disease ..... 222
**Role of biomarkers in the development of personalized nutrition** ..... **222**

**13. Biomarkers of Cancer ..... 224**
**Introduction** ..... **224**
The ideal biomarker for cancer ..... 224
Biomarkers and hallmarks of cancer ..... 225
Single vs multiple biomarkers of cancer ..... 225
**Types of cancer biomarkers** ..... **226**
miRNAs as biomarkers in cancer ..... 226
*Diagnostic value of miRNA in cancer* ..... *228*
Biomarkers of epigenetic gene silencing in cancer ..... 228
*5-hydroxymethylcytosine as a biomarker of cancer* ..... *229*
Carcinoembryonic antigen ..... 229
Circulating cancer biomarkers ..... 229
*Circulating tumor cells as cancer biomarkers* ..... *229*
*Circulating nucleic acids as potential biomarkers of cancer* ..... *230*
*Circulating exosomes and microvesicles as biomarkers of cancer* ..... *230*
*Circulating miRNAs for cancer detection* ..... *230*
DNA repair biomarkers ..... 231
HER3 as biomarker of cancer ..... 231
Immunologic and inflammation biomarkers of cancer ..... 231
Metastatic cancer biomarkers ..... 232
**Molecular diagnostic techniques for cancer** ..... **232**
**Technologies for detection of cancer biomarkers** ..... **234**
Genomic technologies for cancer biomarkers ..... 234
*Biomarkers of PTEN tumor suppressor gene status* ..... *234*
*Cold-PCR* ..... *234*
*ddPCR for detection of cancer biomarkers in cell free plasma DNA* ..... *235*
*Digital karyotyping for cancer biomarkers* ..... *235*
*Genome analysis at the molecular level* ..... *235*
*KRAS as a biomarker of cancer* ..... *236*

*LigAmp for detection of gene mutations in cancer* ..... *236*
*Mitochondrial DNA as a cancer biomarker* ..... *236*
*Next generation squencing for detection of cancer biomarkers* ..... *237*
*Telomerase as a biomarker of cancer* ..... *237*
Tissue microarrays for study of cancer biomarkers ..... 238
Molecular fingerprinting of cancer ..... 238
Proteomic technologies for detecting biomarkers of cancer ..... 239
*2D PAGE* ..... *240*
*Antibody-based detection of protein biomarkers* ..... *240*
*Aptamer-based molecular probes for cancer biomarker discovery* ..... *241*
*Biomarkers of protein-drug interactions in cancer* ..... *241*
*Cancer immunomics to identify autoantibody signatures* ..... *242*
*Desorption electrospray ionization for detection of cancer biomarkers* ..... *242*
*Detection of circulating nucleosomes in serum of cancer patients* ..... *242*
*Detection of tumor biomarkers with ProteinChip technology* ..... *243*
*Glycoprotein biomarkers of cancer* ..... *243*
*HER-2/neu oncoprotein as biomarkers for cancer* ..... *243*
*Humoral proteomics* ..... *244*
*Laser capture microdissection* ..... *244*
*Membrane-type serine protease-1* ..... *244*
*Proteomic analysis of cancer cell mitochondria* ..... *245*
*Proteomic technologies for detection of autoimmune biomarkers* ..... *245*
*SELDI-TOF MS* ..... *246*
*Serum proteome analysis for early detection of cancer* ..... *246*
*Synthetic biomarker-based POC diagnostic for cancer* ..... *246*
*Triple-quadrupole MS for detection of mutant proteins* ..... *246*
*Targeted MS for validation of cancer biomarkers in plasma* ..... *247*
*Tissue proteomics for discovery of cancer biomarkers* ..... *247*
*VeraTag system for cancer biomarkers* ..... *247*
Metabolomic biomarkers of cancer ..... 247
*Magnetic resonance for detecting metabolomics biomarkers of cancer* ..... *248*
*Choline phospholipid biomarkers of cancer* ..... *248*
*Hypoxia-inducible factor-1* ..... *248*
*Detection of drug resistance in cancer by metabolic profiling* ..... *249*
*Plasma free amino acids profiling in cancer* ..... *249*
*Urinary metabolomic biomarkers of cancer* ..... *250*
Epitomics for the early detection of cancer ..... 250
Epigenetic biomarkers of cancer ..... 250
*Detection of biomarkers of DNA methylation* ..... *251*
*Epigenomics Marker Machine for DNA methylation biomarkers* ..... *252*
*Histone deacetylase* ..... *252*
*MDScan™ microarray technology* ..... *252*
*Mucins as epigenetic biomarkers in epithelial cancers* ..... *253*
*PCR with bisulfite for detecting DNA methylation biomarkers in cancer* ..... *253*
*Detection of methylated DNA in serum and urine* ..... *254*
*Integrated platform for genetic and epigenetic analysis* ..... *254*
Nanobiotechnology for early detection of cancer to improve treatment ..... 255
*Aptasensor for electrochemical detection of exosomes* ..... *255*
*Nanowire biosensors for detection of cancer biomarkers* ..... *255*
*NP-peptide complexes for detection of cancer biomarkers in urine* ..... *256*
Ultrasound radiation to enhance release of a tumor biomarker ..... 256
In vivo imaging of cancer biomarkers ..... 257
*Computer tomography* ..... *257*
*Optical systems for in vivo molecular imaging of cancer* ..... *257*
*Positron emission tomography* ..... *257*
*Imaging of tumor oxygenation and microvascular permeability by MRI* ..... *258*
*Xenon-enhanced MRI* ..... *258*
Kallikrein gene family and cancer biomarkers ..... 258
Detection of CTCs as biomarkers of cancer ..... 259
**Applications of cancer biomarkers ..... 260**
Use of biomarkers for cancer classification ..... 260
*Cancer classification using microarrays* ..... *260*
*Proteomic classification of cancer* ..... *260*
Use of biomarkers for early detection of cancer ..... 260
Applications of biomarkers for cancer diagnosis ..... 261
*Methylated DNA sequences as cancer biomarkers* ..... *261*
*MicroRNA expression profiling for diagnosis of human cancers* ..... *262*
*MUC4 as a diagnostic biomarker in cancer* ..... *262*
Applications of biomarkers for cancer diagnosis and therapy ..... 262
*ARTS as a biomarker as well as a basis of anticancer drugs* ..... *264*
*Asparagine synthetase as biomarker for therapy with L-asparaginase* ..... *264*

*Peptide-based agents for targeting cancer biomarkers* ..... *265*
*PI3K mutations as a biomarker for use as a companion diagnostic* ..... *265*
Biomarkers for assessing efficacy of cancer therapy ..... 265
*ERCC1-XPF expression as a biomarker of response to chemotherapy* ..... *265*
*P53 expression level as biomarker of efficacy of cancer gene therapy* ..... *265*
Biomarkers of angiogenesis for developing antiangiogenic therapy ..... 266
*Biomarkers of response to antiangiogenic agents* ..... *266*
*Circulating endothelial cells as targets for antiangiogenic drugs* ..... *266*
*Imaging biomarkers for evaluation of antiangiogenic agents* ..... *267*
*Tumor endothelial biomarkers* ..... *267*
*VEGF signaling inhibitors as biomarkers* ..... *268*
*VEGF-PET imaging for analysis of angiogenic changes within a tumor* ..... *268*
Biomarkers of prognosis in cancer treatment ..... 268
Biomarkers for monitoring cancer therapy ..... 269
Biomarkers of drug resistance in cancer ..... 269
*A systems approach to biomarkers of innate drug resistance* ..... *269*
*Epithelial membrane protein-1 as a biomarker of gefitinib resistance* ..... *270*
*Methylation biomarkers of drug resistance in cancer* ..... *270*
*STAT3 and resistance to cisplatin* ..... *270*
Biomarkers of radiation therapy for cancer ..... 270
**Role of biomarkers in drug development in oncology ..... 271**
Molecular imaging of tumor as a guide to drug development ..... 272
*Use of PET to assess response to anticancer drugs* ..... *272*
*Use of MRI to assess response to anticancer drugs* ..... *273*
Biomarkers in plucked hair for assessing cancer therapy ..... 273
Safety biomarkers in oncology studies ..... 273
Role of biomarkers in phase I clinical trials of anticancer drugs ..... 274
Met receptors as targets for anticancer drugs ..... 274
**Biomarkers according to organ/type of cancer ..... 274**
Bladder cancer biomarkers ..... 274
*Detection of FGFR3 mutations in urine for diagnosis of bladder cancer* ..... *275*
*NMP22 BladderChek* ..... *275*
*Urinary telomerase as biomarker for detection of bladder cancer* ..... *275*
*Concluding remarks abut biomarkers of urinary cancer* ..... *275*
Brain tumor biomarkers ..... 276
*14-3-3zeta positive expression as a prognostic biomarker for GBM* ..... *276*
*ALDH1A3 as a biomarker of GBM* ..... *277*
*Biomarkers to predict response to EGFR inhibitors* ..... *277*
*Biomarkers for predicting recurrence of meningiomas* ..... *277*
*CD133 as biomarker of resistance to radiotherapy* ..... *277*
*Circulating microvesicles as biomarkers* ..... *277*
*CSF attractin as a biomarker of malignant astrocytoma* ..... *278*
*ELTD1 as a biomarker of gliomas* ..... *278*
*Methylation profiling of brain tumors* ..... *278*
*Metabolite biomarkers of brain tumors* ..... *280*
*miRNAs as biomarkers of brain tumors* ..... *280*
*MRI biomarker for response of brain tumor to therapy* ..... *281*
*Multigene predictor of outcome in GBM* ..... *281*
*Neuroimaging biomarkers combined with DNA microarray analysis* ..... *281*
*Proteomic analysis of CSF for identification of biomarkers for gliomas* ..... *281*
*Receptor protein tyrosine phosphatase $\beta$ as biomarker of gliomas* ..... *282*
*Serum protein fingerprinting* ..... *282*
*VEGF-R2 as biomarker of angiogenesis in brain tumors* ..... *282*
*Future prospects of biomarkers of malignant gliomas* ..... *282*
Bone tumor biomarkers ..... 283
*Cytogenetics for the study of bone and soft tissue tumors* ..... *283*
*Biomarkers of Ewing's tumors* ..... *283*
*Role of biomarkers in the diagnosis of bone tumors* ..... *283*
Breast cancer biomarkers ..... 284
*Autoantibody biomarkers of breast cancer* ..... *285*
*Biomarkers of breast cancer in breath* ..... *286*
*Biomarkers for breast cancer in nipple aspiration fluid* ..... *286*
*Circulating tumor DNA as biomarker of breast cancer* ..... *286*
*Circulating exosomes as biomarkers of breast cancer* ..... *286*
*Flow cytometry for quantification of biomarker expression patterns* ..... *287*
*Plasma proteomics for biomarkers of breast cancer* ..... *287*
*Quantitative realtime PCR assays for biomarker validation* ..... *287*
*Cdk6 as a biomarker of breast cancer* ..... *288*
*Centromere protein-F* ..... *288*
*Carbonic anhydrase IX* ..... *289*
*COX-2 as a biomarker of breast cancer* ..... *289*

*G88 as a biomarker of progression of ER+ breast cancer* ..... *289*
*Glycomic biomarkers of breast cancer* ..... *289*
*HER-2/neu oncoprotein* ..... *290*
*High mobility group protein A2* ..... *291*
*Hypermethylated genes as biomarkers of metastatic breast cancer* ..... *291*
*Lipocalin 2 as biomarker of breast cancer progression* ..... *291*
*Long intervening non-coding RNAs* ..... *292*
*Mammaglobin* ..... *292*
*miRNA biomarkers of breast cancer* ..... *292*
*p27 expression as biomarker for survival after chemotherapy* ..... *293*
*Podocalyxin* ..... *293*
*Proneurotensin and Proenkephalin* ..... *294*
*Proliferating cell nuclear antigen* ..... *294*
*Protein kinase C as a predictive biomarker of metastatic breast cancer* ..... *294*
*Retinoblastoma tumor suppressor gene as a biomarker* ..... *294*
*Riboflavin carrier protein* ..... *295*
*Risk of invasive cancer after diagnosis of ductal carcinoma in situ* ..... *295*
*Serum CA 15-3 as biomarker of prognosis in advanced breast cancer* ..... *296*
*Stage-specific embryonic antigen-3* ..... *296*
*Suppressor of deltex protein* ..... *296*
*Tumor microenvironment as biomarker of metastasis in breast cancer* ..... *296*
*Type III TGF-$\beta$ receptor as regulator of cancer progression* ..... *297*
*Diagnostic tests based on breast cancer genes* ..... *297*
*Prognostic role of breast cancer genes* ..... *298*
*Protein biomarkers for breast cancer prevention* ..... *298*
*Biomarkers to evaluate efficacy of chemoprevention* ..... *299*
*Biomarkers of response to chemotherapy of breast cancer* ..... *299*
*Biomarker-guided decisions for breast cancer therapy* ..... *300*
*Concluding remarks and future prospects of breast cancer biomarkers* ..... *300*
Cervical cancer biomarkers ..... 300
Gastrointestinal cancer biomarkers ..... 301
*Esophageal cancer biomarkers* ..... *301*
*Gastric cancer biomarkers* ..... *302*
*Colorectal cancer biomarkers* ..... *303*
Head and neck cancer ..... 308
Leukemia biomarkers ..... 310
*Chromosome translocations in leukemias* ..... *310*
*DNA methylation biomarkers in leukemia* ..... *311*
*Gene mutations as biomarkers in leukemia* ..... *311*
*Molecular diagnostic techniques for leukemia* ..... *311*
*Proteomic technologies for discovering biomarkers of leukemia* ..... *312*
*Biomarkers of chronic lymphocytic leukemia* ..... *312*
*Biomarkers of chronic myeloid leukemia* ..... *313*
*Biomarkers of drug resistance in leukemia* ..... *313*
*Biomarkers of myelodysplasitic syndromes* ..... *313*
Lymphoma biomarkers ..... 314
Liver cancer biomarkers ..... 314
*Biomarkers indicating lower risk of HCC in coffee drinkers* ..... *315*
*Metabonomic profiles discriminate HCC from liver cirrhosis* ..... *315*
*Urinary biomarkers of HCC* ..... *316*
Lung cancer biomarkers ..... 316
*Autoantibodies as biomarkers in lung cancer* ..... *317*
*Biomarkers associated with neuroendocrine differentiation in NSCLC* ..... *318*
*Biomarkers of chronic inflammation in lung cancer* ..... *318*
*Biomarkers for predicting sensitivity to chemotherapy in lung cancer* ..... *318*
*Biomarkers for prediction of sensitivity to EGFR inhibitors* ..... *319*
*CTCs as biomarkers of lung cancer* ..... *320*
*Gene expression profiling for biomarkers of lung cancer* ..... *320*
*Methylation biomarkers of lung cancer* ..... *321*
*miRNA biomarkers in lung cancer* ..... *321*
*Noninvasive detection of lung cancer using exhaled breath.* ..... *322*
*Serum protein biomarkers of lung cancer* ..... *322*
*tNOX as biomarker of lung cancer* ..... *323*
*Tumor-derived DNA and RNA markers in blood* ..... *324*
*Volatile organic compounds in the exhaled breath* ..... *324*
Malignant pleural mesothelioma ..... 324
Melanoma biomarkers ..... 325
Nasopharyngeal carcinoma biomarkers ..... 326
*Proteomic biomarkers of nasopharyngeal cancer* ..... *327*
*miRNA biomarkers of nasopharyngeal carcinoma* ..... *327*
Oral cancer biomarkers ..... 328

Ovarian cancer biomarkers ... 328
*3D microfluidic platform to assess multiple ovarian cancer biomarkers ... 329*
*CA125 as biomarker of ovarian cancer ... 329*
*Epitomics approach for ovarian cancer biomarkers in serum ... 330*
*FGF18 as a biomarker in ovarian cancer ... 330*
*Gene expression studies in ovarian cancer ... 331*
*HE4 protein in urine as a biomarker for ovarian cancer ... 331*
*Hematogenous metastasis of ovarian cancer ... 331*
*HtrA1 as a biomarker of response to chemotherapy in ovarian cancer ... 332*
*Mutation of genes in ovarian cancer ... 332*
*Serum biomarkers of ovarian cancer prognosis ... 332*
*TIM-3 as a biomarker of ovarian cancer ... 332*
*Multiplex assays for biomarkers of ovarian cancer ... 333*
*Concluding remarks on biomarker-based tests of ovarian cancer ... 333*
Pancreatic cancer biomarkers ... 334
*Discovery and validation of pancreatic cancer biomarkers ... 335*
*Cancer stem cells as biomarkers of pancreatic cancer ... 335*
*Circulating exosomes as biomarkers of pancreatic cancer ... 335*
*Histone modifications used as biomarkers in pancreatic cancer ... 335*
*miRNA biomarkers of pancreatic cancer ... 336*
*Macrophage inhibitory cytokine-1 as biomarker of pancreatic cancer ... 337*
*Proteomic biomarkers of pancreatic cancer ... 337*
*Concluding remarks on biomarkers of pancreatic cancer ... 338*
Parathyroid cancer biomarkers ... 338
Peripheral nerve tumors ... 338
*Biomarkers of neurofibromatosis ... 338*
Prostate cancer ... 339
*Adipose tissue-derived biomarkers of obesity-related prostate cancer ... 339*
*B7-H3 as biomarker of prostate cancer ... 340*
*Cancer genetics-guided biomarker signatures of prostate cancer ... 340*
*Detection of prostate cancer biomarkers in urine ... 340*
*Detection of prostatic intraepithelial neoplasia ... 341*
*Epigenetic biomarkers of prostate cancer ... 342*
*Exosomes as biomarkers of prostate cancer ... 342*
*Gene expression analysis of prostate cancer ... 343*
*Genetic biomarkers of prostate cancer ... 343*
*Identification of prostate cancer mRNA biomarkers ... 343*
*Kallikreins as biomarkers of prostate cancer ... 344*
*LCM for diagnosis of prostate cancer ... 344*
*Microarray for diagnosis of prostate cancer ... 345*
*miRNA biomarkers of prostate cancer ... 345*
*Prostate cancer biomarkers in semen ... 346*
*PSA as biomarker of prostate cancer ... 346*
*ProPSA as biomarker of prostate cancer ... 347*
*Prostate Health Index ... 347*
*Prostasomes in blood as biomarker of prostate cancer ... 347*
*PSMA as biomarker of prostate cancer ... 348*
*Sarcosine as a metabolic biomarker of prostate cancer ... 348*
*Silenced CDH13 gene as a biomarker of cancer ... 348*
*Serum-protein fingerprinting ... 348*
*Concluding remarks on biomarkers of prostate cancer ... 349*
Renal cancer biomarkers ... 349
*Gene expression profile of RCC for biomarkers ... 349*
*miRNA biomarkers of renal cancer ... 350*
*Use of proteomics for detection of RCC biomarkers ... 350*
*Use of RCC biomarkers for prognosis and therapy ... 350*
Thyroid cancer biomarkers ... 351
*Detection of BRAF mutation ... 351*
*Gene expression biomarkers of thyroid cancer ... 352*
*miRNA biomarkers of thyroid cancer ... 352*
*Multiple endocrine neoplasia type 2B as risk factor for thyroid cancer ... 352*
**Role of the NCI in cancer biomarkers ... 353**
**Future prospects for cancer biomarkers ... 354**
Cancer biomarker research at academic institutions ... 354
Future challenges in the discovery of cancer biomarkers ... 354

**14. Biomarkers of Disorders of the Nervous System ... 356**
**Introduction ... 356**
**Discovery of biomarkers for neurological disorders ... 356**
Biomarker identification in the CSF using proteomics ... 357
Biomarker identification in the CSF using lipidomics ... 357

Cerebral microdialysis for the study of biomarkers of cerebral metabolism ..... 358
Detection of protein biomarkers of CNS disorders in the blood ..... 358
Genomic technologies for study of biomarkers of neurological disorders ..... 358
Brain imaging for detection of biomarkers ..... 359
**Biomarkers of the aging brain ..... 359**
Cellular biomarker of aging of the brain ..... 359
CSF F2-isoprostanes as biomarker of aging brain ..... 359
IL-6 as a biomarker of cognitive impairment with aging ..... 360
Protein aggregation as a biomarker of aging brain ..... 360
Telomere shortening as a biomarker of aging brain and dementia ..... 360
**Data mining for biomarkers of neurological disorders ..... 361**
**Antibodies as biomarkers in disorders of the nervous system ..... 361**
**Biomarkers of neural regeneration ..... 361**
**Biomarkers of disruption of blood-brain barrier ..... 362**
**Biomarkers of neurotoxicity ..... 362**
Glial fibrillary acidic protein as biomarker of neurotoxicity ..... 363
Single-stranded DNA as a biomarker of neuronal apoptosis ..... 363
**Biomarkers of neurogenetic disorders ..... 363**
Charcot-Marie Tooth disease ..... 364
Duchenne and Becker muscular dystrophy ..... 365
Early-onset torsion dystonia ..... 365
Fragile X syndrome ..... 366
Genetic neurotransmitter disorders ..... 366
Hereditary neuropathy with liability to pressure palsies ..... 366
Hereditary metabolic storage disorders with neurologic manifestations ..... 367
*Gaucher disease ..... 367*
*Pompe's disease ..... 367*
Mitochondrial disorders affecting the nervous system ..... 367
Spinal muscular atrophy ..... 368
*Biomarkers of SMA ..... 368*
**Biomarkers of neurodegenerative disorders ..... 369**
**Biomarkers of dementia ..... 369**
Biomarkers of vascular dementia ..... 370
**Biomarkers of Alzheimer's disease ..... 370**
The ideal biomarker for AD ..... 372
Methods for determining biomarkers of AD ..... 372
*Gene expression patterns in AD ..... 372*
*Magnetic resonance spectroscopy in AD ..... 373*
*MicroRNAs as biomarkers of neurodegenerative disorders ..... 373*
*MRI for biomarkers of AD ..... 374*
*Nanotechnology to measure Aβ-derived diffusible ligands ..... 375*
*PET scanning for biomarkers of AD ..... 375*
*Simultaneous measurement of several biomarkers for AD ..... 377*
*Targeting of chemokine receptor as biomarker for brain imaging ..... 377*
Biomarkers of AD in CSF ..... 378
*CSF sulfatide as a biomarker for AD ..... 378*
*CSF Reelin as biomarker of AD ..... 378*
*Monitoring of synthesis and clearance rates of Aβ in the CSF ..... 378*
*Protein biomarkers of AD in CSF ..... 379*
*Tau proteins in CSF ..... 380*
*Tests for the detection of Aβ in CSF ..... 380*
*Tests combining CSF tau and Aβ ..... 381*
Blood biomarkers of AD ..... 382
*A serum protein-based algorithm for the detection of AD ..... 382*
*Amyloid precursor protein ..... 382*
*Detection of aggregated misfolded proteins in the blood ..... 382*
*Lipid biomarkers for preclinical detection of AD ..... 383*
*Lymphocyte Proliferation Test ..... 383*
*Metabolomic biomarker profiling ..... 383*
*Plasma protein biomarkers of AD ..... 383*
*Protein kinase C in red blood cells ..... 384*
Urine tests for AD ..... 384
A biomarker-based skin test for AD ..... 385
Salivary biomarkers of AD ..... 385
Applications of biomarkers of AD ..... 385
*Biomarker changes in autosomal dominantly inherited AD ..... 385*
*Correlation of imaging biomarkers with CSF biomarkers of AD ..... 386*
*Genetic tests for AD ..... 386*
*Humanin as a biomarker as well as neuroprotective in AD ..... 387*
*Plasma biomarkers of drug response in AD ..... 387*
*PredictAD project ..... 387*

*TOMM40 gene and risk of AD* ... *388*
*Use of biomarkers to predict AD in patients with MCI* ... *388*
Concluding remarks about biomarkers for AD and future prospects ... 389
**Biomarkers of Parkinson's disease ... 390**
Autoantibodies as biomarkers of PD ... 391
Biomarkers of PD based on gene expression in blood ... 391
Cardiac denervation as a biomarker of PD ... 391
Genetic biomarkers of PD ... 391
Imaging biomarkers of PD ... 392
Metabolic brain networks as biomarkers ... 393
Metabonomic biomarker profile for diagnosis and monitoring of PD ... 393
Protein biomarkers of PD ... 393
*P11 protein as a biomarker of depression in PD* ... *394*
Serum vitamin D as a biomarker of PD ... 394
Biomarkers of prodromal PD ... 395
Future needs for biomarkers of PD ... 395
**Biomarkers of Huntington's disease ... 396**
Genetic biomarker of HD progression ... 397
Quantitative MRI measurement of brain atrophy as biomarker of HD ... 397
Metabolic networks as biomarkers of preclinical Huntington disease ... 397
**Biomarkers of Wilson's disease ... 398**
**Biomarkers of amyotrophic lateral sclerosis ... 398**
ALS biomarker detection in blood vs CSF ... 399
Biomarkers of neuroinflammation in ALS ... 399
Genetic biomarkers of ALS ... 399
Imaging biomarkers of ALS ... 400
Metabolomic biomarkers of ALS ... 400
Proteomic biomarkers of ALS ... 401
Ideal biomarker of ALS ... 401
Future of biomarkers of ALS ... 401
**HIV-1-associated neurocognitive disorders ... 402**
Biomarkers of dementia in HIV-1-infected patients ... 402
**Biomarkers of autoimmune encephalitis ... 402**
**Biomarkers of prion diseases ... 402**
14-3-3 protein and tTau/P-Tau ratio ... 403
Bioluminescence imaging as a surrogate biomarker of prion infectivity ... 403
miRNAs as biomarkers of prion-induced neurodegeneration ... 403
Prion protein detection by real-time quaking-induced conversion ... 404
Prions in the urine of patients with variant CJD ... 404
**Biomarkers of multiple sclerosis ... 404**
Antibodies in multiple sclerosis ... 405
*Antibodies to galactocerebroside* ... *406*
*Antibodies to myelin oligodendrocyte glycoprotein* ... *406*
Brain N-acetylaspartylglutamate as biomarker of cognitive function in MS ... 406
Brain imaging biomarkers of multiple sclerosis ... 406
*MRI biomarkers of multiple sclerosis* ... *406*
*Molecular imaging* ... *407*
Biomarkers of response to therapy of multiple sclerosis ... 407
*DNA motifs in the blood as biomarkers of response to treatment* ... *407*
*Gene expression* ... *408*
*Lymphocyte subsets as biomarkers of therapeutic response* ... *409*
*Neurofilaments* ... *409*
*Vitamin D as predictor of activity and progression of MS* ... *409*
CSF biomarkers in multiple sclerosis ... 409
CSF Cystatin C as a biomarker of multiple sclerosis ... 409
Detecting autoantibodies in multiple sclerosis ... 410
*Switch-associated protein 70 antibodies in multiple sclerosis* ... *410*
Gelsolin as a biomarker of multiple sclerosis ... 410
Matrix metalloproteinases as biomarkers in multiple sclerosis ... 410
Oligoclonal bands as biomarkers of MS ... 411
Serum proteomic pattern analysis in multiple sclerosis ... 411
T cells as biomarkers of multiple sclerosis ... 411
Concluding remarks and future perspective for biomarkers of multiple sclerosis ... 411
**Biomarkers of cerebrovascular disorders ... 412**
Biomarkers of stroke ... 412
*Etiological biomarkers of ischemic stroke* ... *414*
*Brain natriuretic peptide as a biomarker for cardioembolic stroke* ... *415*
*Brain lactate and N-acetylaspartate as biomarkers of stroke* ... *415*
*CRP as biomarker of risk of stroke* ... *415*
*CSF biomarkers in acute stroke* ... *416*
*Gene expression in blood following ischemic stroke* ... *416*

*Glutathione S-Transferase-π* ..... *416*
*Intercellular adhesion molecule 1 as biomarker of ischemic stroke* ..... *417*
*Lp-PLA2 and CRP as biomarkers for stroke* ..... *417*
*Matrix metalloproteinase-9* ..... *417*
*miRNAs as biomarkers of stroke* ..... *417*
*Neuroserpin polymorphisms as a biomarker of stroke* ..... *417*
*NMDA receptors as biomarkers of excitotoxicity in stroke* ..... *418*
*Nucleosomes as biomarkers of stroke* ..... *418*
*PARK7 and nucleoside diphosphate kinase A as biomarkers of stroke* ..... *418*
*Visinen-like protein 1* ..... *419*
*Biomarker panels for stroke* ..... *419*
*Future prospects for biomarkers of stroke* ..... *419*
Biomarkers of cerebral vasospasm ..... 420
Biomarkers of intracerebral hemorrhage ..... 420
Biomarkers of hypoxic brain damage ..... 421
Biomarkers of ischemic brain damage ..... 421
D-dimer as a biomarker of cerebral venous thrombosis ..... 421
**Biomarkers of traumatic brain injury ..... 422**
Technologies for identification of biomarkers of TBI ..... 422
*Cerebral microdialysis for study of biomarkers of TBI* ..... *422*
*Proteomic technologies for biomarkers of TBI* ..... *423*
*Systemy biology approach for discovery of biomarkers of TBI* ..... *424*
Biomarkers of TBI ..... 424
*Aβ as a biomarker of TBI* ..... *425*
*Diffusion tensor imaging in TBI* ..... *425*
*Glial fibrillary acidic protein as biomarker of TBI* ..... *425*
*Hyperphosphorylated axonal neurofilament protein* ..... *425*
*IL-6 and nerve growth factor as biomarkers of TBI* ..... *426*
*Myelin basic protein* ..... *426*
*Neurofilament heavy chain* ..... *426*
*Serum S100β as biomarker of TBI.* ..... *426*
*SNTF as a biomarker for predicting cognitive decline after mild TBI* ..... *427*
*Tau as biomarker of TBI* ..... *427*
*Ubiquitin C-terminal Hydrolase-L1* ..... *428*
Biomarkers of inflicted TBI in infants ..... 428
Biomarkers of concussion ..... 428
Clinical applications of biomarkers of TBI ..... 429
**Biomarkers of CNS infections ..... 429**
Biomarkers of bacterial meningitis ..... 429
Biomarkers of viral infections of CNS ..... 430
*Biomarkers of CNS HIV infection* ..... *430*
*CSF kynurenic acid level as a biomarker of tick-borne encephalitis* ..... *431*
**Biomarkers of epilepsy ..... 431**
Biochemical markers of epilepsy ..... 431
Biomarkers of temporal lobe epilepsy ..... 432
Biomarkers of drug-resistant epilepsy ..... 432
Genetic epilepsies ..... 432
Electrophysiological biomarkers of epilepsy ..... 432
Imaging biomarkers of epilepsy ..... 433
Protein biomarkers of inflammation in epilepsy ..... 433
**Biomarkers of normal pressure hydrocephalus ..... 434**
**Biomarkers of pseudotumor cerebri ..... 434**
**Biomarkers of retinal disorders ..... 434**
Biomarkers of age-related macular degeneration ..... 435
**Biomarkers of sleep disorders ..... 436**
Biomarker of excessive daytime sleepiness ..... 436
Biomarkers of obstructive sleep apnea ..... 436
Biomarkers of restless legs syndrome ..... 436
**Biomarkers of pain ..... 437**
Biomarkers of disorders with musculoskeletal pain ..... 437
Biomarkers of neuropathic pain ..... 438
Brain insular glutamate as biomarker of fibromyalgia ..... 438
Biomarkers of visceral pain ..... 438
Biomarkers of migraine ..... 439
**Biomarkers of myalgic encephalomyelitis/chronic fatigue syndrome ..... 439**
**Biomarkers of psychiatric disorders ..... 440**
Anorexia nervosa ..... 440
Attention-deficit hyperactivity disorder ..... 441
Biomarkers of autism ..... 441
*Epigenetics of ASD* ..... *442*
*Gastrointestinal microbiota disturbances and ASD* ..... *442*

*Genetic factors in ASD* ... *442*
*Immune biomarkers of ASD* ... *442*
*Metabolic disturbances in autism* ... *442*
*Neurophysiological biomarkers* ... *443*
*Role of oxidative stress in autism* ... *443*
*Test for ASD based on a 55-gene expression panel* ... *444*
*Umbilical cord biomarkers* ... *444*
Biomarkers of bipolar disorder ... 444
Biomarkers of depression ... 445
*Biochemical biomarkers of depression* ... *445*
*Biomarkers and response to antidepressant treatment* ... *446*
*Cingulate cortex activity and response to antidepressants* ... *446*
*Genetic biomarkers of response to antidepressants* ... *446*
*Inflammatory biomarkers of depression and psychosis* ... *447*
*P11 as a biomarker of depression* ... *447*
*Panels of blood-based biomarkers for diagnosis of MDD* ... *447*
*Plasma metabonomics for diagnosis of MDD* ... *448*
*Post-partum depression* ... *448*
Biomarkers of posttraumatic stress disorder ... 448
Biomarkers of psychosis ... 449
Biomarkers of schizophrenia ... 450
*Biomarkers of abnormalities of visual information processing* ... *450*
*Genetic biomarkers of schizophrenia* ... *451*
*Gene expression analysis of blood for biomarkers of schizophrenia* ... *451*
*Metabolic biomarkers of schizophrenia* ... *451*
*Proteomic studies for biomarkers of schizophrenia* ... *451*
Biomarkers of suicide ... 452

**15. Biomarkers of Cardiovascular Disorders ... 454**
**Epidemiology of cardiovascular disease ... 454**
**Biomarkers of cardiovascular diseases ... 454**
Biomarkers of acute myocardial infarction ... 456
Genetic biomarkers of cardiovascular disorders ... 456
**Methods for identification of cardiovascular biomarkers ... 458**
Application of proteomics for biomarkers of cardiovascular disease ... 458
*Targeted MS-based pipeline approach* ... *458*
*Cardiovascular disease biomarker panel* ... *459*
Detection of biomarkers of myocardial infarction in saliva by a nanobiochip ... 459
Metabolomic technologies for biomarkers of myocardial ischemia ... 459
Imaging biomarkers of cardiovascular disease ... 459
*Annexin A5 as an imaging biomarker of cardiovascular disease* ... *460*
*Cardiovascular MRI* ... *460*
*Cardiovascular hybrid imaging* ... *460*
*Myocardial perfusion imaging* ... *460*
Implantable magnetic biosensors for detecting cardiac biomarkers ... 461
**Applications of biomarkers of cardiovascular disease ... 461**
Biomarkers for ischemic heart disease and myocardial infarction ... 461
*Troponin* ... *462*
*Natriuretic peptide* ... *463*
*Copeptin* ... *464*
*Creatine kinase muscle brain* ... *465*
*miRNAs as biomarkers of acute coronary syndrome* ... *465*
*Myoglobin* ... *465*
*Fatty acid binding protein* ... *465*
*Growth Differentiation Factor-15* ... *466*
*High density lipoprotein 2* ... *466*
*Cripto-1 as a biomarker of myocardial infarction* ... *466*
*Cataract as a biomarker of ischemic heart disease* ... *466*
*Plasma CD93 as a biomarker for coronary artery disease* ... *467*
*Plasma fetuin-A levels and the risk of myocardial infarction* ... *467*
*YKL-40 as an inflammatory biomarker in ischemic heart disease* ... *467*
Biomarkers of cardiomyopathy ... 467
*miRNA biomarkers of peripartum cardiomyopathy* ... *467*
*Takotsubo cardiomyopathy* ... *468*
*Troponin T levels in hypertrophic cardiomyopathy* ... *468*
Biomarkers of heart failure ... 468
*Annexin A5 for prognosis of heart failure* ... *468*
*Angiogenesis biomarkers* ... *469*
*β-2a protein as a biomarker of heart failure* ... *469*
*Desmin* ... *469*
*Galectin-3 as biomarker of acute heart failure* ... *469*

*G protein-coupled receptor kinase-2 as biomarker of CHF* ..... *470*
*KIF6 gene as biomarker of heart failure* ..... *470*
*Metabolic biomarkers of heart failure* ..... *471*
*miRNA biomarkers of heart failure.* ..... *471*
*Natriuretic peptide as biomarker of heart failure* ..... *471*
*Oxidative stress as biomarker of heart failure* ..... *472*
*Future prospects for biomarkers of heart failure.* ..... *472*
Biomarkers for atherosclerosis ..... 472
*9p21-3 locus and coronary atherosclerosis* ..... *472*
*Adipocyte enhancer-binding protein 1* ..... *473*
*Gene signatures on leucocytes as biomarkers of atherosclerosis* ..... *473*
*Ghrelin as a biomarker of atherosclerosis* ..... *474*
*Imaging biomarkers of hypercholesterolemia/atherosclerosis* ..... *474*
*Inflammatory biomarkers of atherosclerosis* ..... *474*
*Lipid-modified proteins as biomarkers of atherosclerosis* ..... *474*
*Lp-PLA2 as biomarker of atherosclerotic heart disease* ..... *474*
*Metabolomic profile in hypercholesterolemia* ..... *475*
*Nitric oxide impairment and atherosclerosis* ..... *475*
*Oxygen free radicals as biomarkers of atherosclerosis* ..... *475*
*Proteomic profiles of serum inflammatory biomarkers of atherosclerosis* ..... *475*
Biomarkers of coronary heart disease ..... 476
*Apolipoproteins as risk factors for coronary heart disease* ..... *476*
*CRP as biomarker of risk for coronary heart disease* ..... *476*
*High level of blood ceramides as a biomarker of CHD* ..... *477*
*Impairment of EPCs by oxidative stress as a biomarker of disease* ..... *477*
*Role of TNF in acute coronary syndromes* ..... *478*
*Serum parathyroid hormone as biomarker of CHD* ..... *478*
*Serum stem cell factor as a biomarker of CHD* ..... *478*
*VILCAD biomarker score for prediction of long-term mortality in CHD* ..... *478*
Biomarkers for pulmonary arterial hypertension ..... 479
Biomarkers of abdominal aortic aneurysm ..... 479
**Biomarkers of thrombotic disorders ..... 481**
Biomarkers of arterial thromboembolism ..... 481
*Nanoparticles as synthetic biomarkers of thrombus formation* ..... *481*
Biomarkers of venous thromboembolism ..... 481
*BNP and cTnT as biomarkers of outcome in pulmonary embolism* ..... *481*
*D-dimer as biomarker of venous thromboembolism* ..... *482*
*Molecular biomarkers of venous thromboembolism* ..... *482*
Genetic biomarkers for cardiovascular disease ..... 482
*Biomarkers of inherited cardiomyopathies* ..... *482*
*Gene mutations in pulmonary arterial hypertension* ..... *482*
*Gene variant as a risk factor for sudden cardiac death* ..... *483*
*Genetic biomarkers of early onset myocardial infarction* ..... *483*
*Genetic biomarkers of atherosclerosis* ..... *483*
*IL-1 gene polymorphism as biomarker of cardiovascular disease* ..... *484*
*IL-6R signaling pathway and coronary heart disease* ..... *484*
*Kallikrein gene mutations in cardiovascular disease* ..... *484*
*Kallikrein gene and essential hypertension.* ..... *485*
*Mutations in the low density lipoprotein receptor gene* ..... *485*
*Mutations within several genes that code for ion channel* ..... *485*
*Polymorphisms of the eNOS gene and angina pectoris* ..... *486*
*Lipoprotein (a) genetics* ..... *486*
*Polymorphisms in the apolipoprotein C gene* ..... *486*
*Polymorphisms in the apolipoprotein E gene* ..... *487*
*Polymorphism in the angiotensinogen gene* ..... *487*
Multiple biomarkers for prediction of death from cardiovascular disease ..... 487
**Role of biomarkers in the management of cardiovascular disease ..... 488**
Biomarkers in the diagnosis/prognosis of myocardial infarction ..... 488
Biomarkers for prevention of cardiovascular disease ..... 488
C reactive protein as biomarker of response to statin therapy ..... 490
HSP72 and eNOS as biomarkers of cardioprotective effect of HBO ..... 490
Multimarker panel for prognosis in chronic heart failure ..... 491
Molecular signature analysis in management of cardiovascular diseases ..... 491
Presage ST2 Assay ..... 491
Role of circulating biomarkers and mediators of cardiovascular dysfunction ..... 492
Use of protein biomarkers for monitoring acute coronary syndromes ..... 492
Use of biomarkers for prognosis of recurrent atrial fibrillation ..... 492
Use of multiple biomarkers for monitoring of cardiovascular disease ..... 493
Use of biomarkers in the management of peripheral arterial disease ..... 493
Use of biomarkers in the management of hypertension ..... 493
**Systems approach to cardiovascular biomarker research ..... 494**

**16. Biomarkers of Pulmonary Diseases ..... 496**
**Introduction ..... 496**
Association of biomarkers of inflammation with lung function in the elderly ..... 496
Biomarkers of oxidative stress in lung diseases ..... 497
Biomarkers of community-acquired pneumonia ..... 497
Biomarkers of acute lung injury and respiratory distress syndrome ..... 497
*Cytokine/chemokine biomarkers of SARS ..... 497*
*Plasma biomarkers related to inflammation ..... 498*
*Urinary NO as biomarker ..... 498*
Biomarkers of interstitial lung disease ..... 498
*Pulmonary surfactant proteins as biomarkers for lung diseases ..... 498*
*Serum KL-6 as biomarker of interstitial lung disease ..... 499*
Biomarkers of chronic obstructive pulmonary disease ..... 499
*Alpha1-antitrypsin gene polymorphisms predisposing to emphysema ..... 499*
*Biomarkers of extracellular matrix turnover in COPD ..... 500*
*Biomarkers of lung failure in COPD ..... 500*
*BNP as a biomarker of chronic pulmonary disease ..... 500*
*Chromagranin A (CgA) as biomarker of airway obstruction in smokers ..... 501*
*C-reactive protein as a biomarker of COPD ..... 501*
*Gene expression profile in peripheral blood of patients with COPD ..... 501*
*Hyperuricemia as a biomarker of early mortality in COPD ..... 501*
*Increased expression of PIGF as a biomarker of COPD ..... 501*
Biomarkers of asthma ..... 502
*Biomarker for rhinovirus-induced asthma exacerbation ..... 502*
*Biomarkers for predicting response to corticosteroid therapy ..... 502*
*Comparison of biomarkers of asthma and COPD ..... 502*
*Cytokines as biomarkers of asthma severity ..... 503*
*Exaled NO as a biomarker of asthma ..... 503*
*Endothelin-1 in exhaled breath as biomarker of asthma ..... 504*
*IgE as guide to dosing of omalizumab for asthma ..... 504*
*Periostin as a biomarker for treatment of asthma with lebrikizumab ..... 504*
Biomarkers of cystic fibrosis ..... 505

**17. Biomarkers in Gynecology and Obstetrics ..... 506**
**Introduction ..... 506**
**Biomarkers of menopause ..... 506**
**Biomarkers of premenstrual dysphoric disorder ..... 506**
**Biomarkers of endometriosis ..... 507**
**Biomarkers for preeclampsia ..... 507**
Pathogenesis of preeclampsia ..... 507
Metabolomic biomarkers in urine in preeclampsia ..... 508
Protein biomarker of preeclampsia in urine ..... 508
Protein biomarkers of preeclampsia in CSF ..... 509
Protein HtrA1 as a biomarker for preeclampsia ..... 509
Placental growth factor as a biomarker for preeclampsia ..... 510
sFlt1 and soluble endoglin as biomarkers of preeclampsia ..... 510
RNA biomarkers ..... 510
Genes associated with preeclampsia ..... 511
**Biomarkers of premature birth ..... 511**
Proteomic biomarkers of premature birth ..... 511
**Biomarkers of oxidative stress in complicated pregnancies ..... 512**
**Fetal biomarkers in maternal blood ..... 512**
**Metabolic biomarkers of prenatal disorders in the mother ..... 513**

**18. Biomarkers & Personalized Medicine ..... 514**
**Introduction ..... 514**
**Pharmacogenetics ..... 514**
Biomarkers and pharmacogenetics ..... 515
**Pharmacogenomics ..... 516**
**Pharmacoproteomics ..... 517**
Single cell proteomics for personalized medicine ..... 517
**Role of biomarkers in development of personalized drugs ..... 518**
Metabolomic biomarker-based drug discovery ..... 518
Use of biomarkers for developing MAb therapy in oncology ..... 518
**Biomarker tests for molecularly targeted therapies ..... 519**
**Biobanking, biomarkers and personalized medicine in EU ..... 519**
**Bioinformatics to sort biomarker data for personalized medicine ..... 521**
**Biomarkers for monitoring response to therapy ..... 521**
**Drug rescue by biomarker-based personalized medicine ..... 521**
**Future role of biomarkers in personalized medicine ..... 522**

**19. Biomarkers and Regulatory issues ..... 524**
**Introduction ..... 524**
**Biomarker validation ..... 524**
FDA criteria for a valid biomarker ..... 524
FDA letter of support for biomarkers ..... 526
Role of NIST in validation of cancer biomarkers ..... 527
Quality specifications for BNP and NT-proBNP as cardiac biomarker assays ..... 527
National Biomarker Development Alliance ..... 527
**FDA perspective of biomarkers in clinical trials ..... 528**
**FDA and predictive medicine ..... 529**
**Biomarkers and FDA's Voluntary Genomic Data Submission ..... 530**
**Role of imaging biomarkers in approval of drugs ..... 530**
**Regulatory oversight of biomarker tests for targeted therapies ..... 531**
**FDA and biomarkers ..... 531**
FDA consortium linking genetic biomarkers to serious adverse events ..... 531
Oncology Biomarker Qualification Initiative ..... 532
Critical Path Initiative ..... 532
Predictive Safety Testing Consortium ..... 534
The 21st Century Cures Act and biomarkers ..... 534
From validated biomarker assay to a clinical laboratory diagnostic ..... 535
Fast Path programs ..... 536
Regulatory challenges in the biomarker field ..... 536
FDA requirements of biomarkers and companion diagnostics ..... 537

**20. References ..... 538**

## Tables

Table 1-1: Historical landmarks in discovery and development of biomarkers ..... 31
Table 1-2: Classification of biomarkers ..... 31
Table 1-3: Terminology of clinically relevant biomarkers of disease ..... 33
Table 1-4: Autoimmune disorders under study for autoantibodies as predictors ..... 43
Table 1-5: Comparison of various types of biomarkers ..... 43
Table 1-6: Various "omics" technologies for discovery of biomarkers ..... 45
Table 1-7: Role of biomarkers in translational medicine ..... 46
Table 2-1: Classification of methods of gene expression analysis ..... 49
Table 2-2: Comparison of proteomic profiling technologies for discovery of biomarkers ..... 75
Table 2-3: Companies involved in developing molecular imaging ..... 86
Table 3-1: Applications of biochip/microarray technology in relation to biomarkers ..... 108
Table 4-1: Companies using metabolomics for drug discovery ..... 122
Table 4-2: Causes of failures in clinical trials and their reduction by use of biomarkers ..... 128
Table 4-3: Biomarker-based drug development at major pharmaceutical companies ..... 129
Table 5-1: Metabolic biomarkers of inflammatory diseases ..... 138
Table 5-2: Oxidized phospholipids as biomarkers of various diseases ..... 139
Table 5-3: Examples of biomarkers common to multiple diseases ..... 153
Table 5-4: Examples of use of biomarkers in animal health ..... 155
Table 6-1: Biomarkers of diabetes mellitus ..... 159
Table 8-1: miRNAs deregulated in rheumatoid arthritic tissues ..... 179
Table 8-2: Classification of inflammatory biomarkers in osteoarthritis ..... 182
Table 9-1: Biomarkers of sepsis ..... 191
Table 11-1: Biomarkers of aging ..... 208
Table 12-1: Nutritional biomarkers ..... 217
Table 13-1: Desirable characteristics of biomarkers for cancer ..... 224
Table 13-2: Types of cancer biomarkers ..... 226
Table 13-3: A classification of molecular diagnostic methods in cancer ..... 233
Table 13-4: Cancer biomarkers used for diagnosis and therapy ..... 263
Table 13-5: Novel biomarkers of prognosis in cancer treatment ..... 268
Table 13-6: Biomarkers of brain tumors ..... 276
Table 13-7: Biomarkers of breast cancer ..... 284
Table 13-8: miRNA associated with breast cancer ..... 292
Table 13-9: Biomarkers of colorectal cancer ..... 303
Table 13-10: Biomarkers of lung cancer ..... 316
Table 13-11: Classification of biomarkers of melanoma ..... 325
Table 13-12: Biomarkers of nasopharyngeal carcinoma and potential applications ..... 326
Table 13-13: Biomarkers of ovarian cancer ..... 329
Table 13-14: Classification of biomarkers of pancreatic cancer ..... 334
Table 13-15: Biomarkers of prostate cancer ..... 339
Table 14-1: Biomarkers of cerebral metabolism ..... 358
Table 14-2: Classification of biomarkers of Alzheimer disease in blood and CSF ..... 370

Table 14-3: Characteristics of an ideal biomarker for Alzheimer disease ..... 372
Table 14-4: miRNA expression in neurodegenerative diseases ..... 373
Table 14-5: Biomarkers of Parkinson disease ..... 390
Table 14-6: Biomarkers of Huntington disease ..... 396
Table 14-7: Classification of biomarkers of amyotrophic lateral sclerosis ..... 398
Table 14-8: Biomarkers of multiple sclerosis ..... 404
Table 14-9: Gene expression as biomarker of response to interferon-β in multiple sclerosis ..... 408
Table 14-10: Biomarkers of stroke ..... 413
Table 14-11: Etiological blood biomarkers of ischemic strokes due to large artery atherosclerosis ..... 414
Table 14-12: Biomarkers of traumatic brain injury ..... 424
Table 14-13: Biomarkers of epilepsy ..... 431
Table 14-14: Biomarkers of autism spectrum disorder ..... 441
Table 14-15: Biomarkers of response to antidepressant treatment ..... 446
Table 14-16: Biomarkers of posttraumatic stress disorder ..... 448
Table 15-1: Classification of biomarkers for cardiovascular diseases ..... 455
Table 15-2: Genes that cause cardiovascular diseases ..... 457
Table 15-3: Biomarkers of abdominal aortic aneurysm ..... 480
Table 15-4: Biomarkers for cardiovascular disease risk prediction ..... 488
Table 16-1: Biomarkers of pulmonary diseases ..... 496
Table 18-1: Pharmacogenetic vs. pharmacogenomic studies ..... 515
Table 18-2: Applications of pharmacoproteomic biomarkers in personalized medicine ..... 517
Table 19-1: Issued letters of support for biomarkers by the FDA ..... 526
Table 19-2: Drugs requiring biomarker/companion diagnostic information in the label ..... 537

## Figures

Figure 1-1: Relation of biomarkers to other technologies and healthcare ..... 46
Figure 1-2: Role of biomarkers in monitoring of diseases ..... 47
Figure 2-1: The central role of spectrometry in proteomics ..... 58
Figure 2-2: Selected reaction monitoring workflow for verification of biomarkers ..... 72
Figure 4-1: Role of biomarkers in drug discovery and development process ..... 112
Figure 5-1: Diseases associated with myositis autoantibodies ..... 154
Figure 6-1: Plasma lipids in metabolic syndrome ..... 165
Figure 8-1: β-CrossLaps bone resorption biomarker assay ..... 185
Figure 13-1: Role of proteomics in the discovery of cancer biomarkers ..... 240
Figure 13-2: Nanowire biosensor for cancer diagnosis ..... 256
Figure 13-3: Cancer biomarker development and validation ..... 354
Figure 14-1: Discovery and application of biomarkers in neurological diseases ..... 356
Figure 14-2: A scheme of pathogenesis of MDD with relevant biomarkers ..... 445
Figure 15-1: Biomarkers of acute myocardial infarction related to pathophysiology ..... 456
Figure 18-1: Role of pharmacogenetic biomarkers in personalized medicine ..... 516
Figure 18-2: Workflow for developing metabolomics-based biomarkers for personalized treatment ..... 518
Figure 18-3: Impact of biomarkers on personalized medicine ..... 522
Figure 19-1: Stages and timelines of biomarker discovery, development and marketing ..... 524
Figure 19-2: Biomarker qualification pilot process at the FDA ..... 526
Figure 19-3: From a validated biomarker assay to a clinical laboratory diagnostic ..... 535

## Abbreviations

| | |
|---|---|
| 2D GE | 2-dimensional gel electrophoresis |
| AD | Alzheimer's disease |
| BNP | B-type natriuretic peptide |
| CHD | coronary heart disease |
| CHF | congestive heart failure |
| CNS | central nervous system |
| CO | carbon monoxide |
| CRADA | cooperative research and development agreement (between a US federal laboratory and one or more non-federal parties) |
| CRP | C-reactive protein |
| CSF | cerebrospinal fluid |
| CT | computer tomography |
| CTC | circulating tumor cell |
| DT-MRI | diffusion-tensor MRI |
| EGFR | epithelial growth factor receptor |
| ELISA | Enzyme-linked immunosorbent assay |
| EST | expressed sequence tags |
| FDA | Food and Drug Administration, USA |
| FFPE | formalin-fixed paraffin-embedded |
| FISH | fluorescent in situ hybridization |
| fMRI | functional magnetic resonance imaging |
| GC | gas chromatography |
| GFAP | glial fibrillary acidic protein |
| GWAS | genome-wide association study |
| $H_2S$ | hydrogen sulfide |
| Hs-CRP | high sensitivity C-reactive protein |
| IHC | Immunohistochemistry |
| IL | interleukin |
| KRAS | Kirsten rat sarcoma viral oncogene homolog |
| LC | liquid chromatography |
| LCM | laser capture microdissection |
| LDH | lactic dehydrogenase |
| LDT | Laboratory Developed Test |